NC
QNCX icon

NinePointTwo Capital’s Quince Therapeutics QNCX Stock Holding History

NinePointTwo Capital’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-64
Closed -$28K – 220
2022
Q2 		$28K Hold
64
– – 0.01% 196
2022
Q1 		$79K Buy
+64
New +$87.1K 0.02% 206

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

NinePointTwo Capital's QNCX Position: Q3 2022 in Review

NinePointTwo Capital sold out of Quince Therapeutics (QNCX) in Q3 2022, closing a stake of 64 shares — an estimated $28K sold.

NinePointTwo Capital first reported a position in QNCX in Q1 2022 and held it in 2 quarters. The position peaked at $79K in Q1 2022. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

  • NinePointTwo Capital reported no remaining Quince Therapeutics position as of Q3 2022 after selling out during the quarter.
  • NinePointTwo Capital sold 64 Quince Therapeutics shares in Q3 2022, an estimated $28K.
  • NinePointTwo Capital first reported a position in Quince Therapeutics in Q1 2022 and held it in 2 quarters.
  • NinePointTwo Capital's Quince Therapeutics position peaked at $79K in Q1 2022.
  • 58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on NinePointTwo Capital's 13F filing for Q3 2022, filed 14 Nov 2022.